199 related articles for article (PubMed ID: 24443787)
1. Th17 and Treg cells in adolescents with Graves' disease. Impact of treatment with methimazole on these cell subsets.
Klatka M; Grywalska E; Partyka M; Charytanowicz M; Kiszczak-Bochynska E; Rolinski J
Autoimmunity; 2014 May; 47(3):201-11. PubMed ID: 24443787
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Graves' disease with methimazole in children alters the proliferation of Treg cells and CD3+ T lymphocytes.
Klatka M; Kaszubowska L; Grywalska E; Wasiak M; Szewczyk L; Foerster J; Cyman M; Rolinski J
Folia Histochem Cytobiol; 2014; 52(1):69-77. PubMed ID: 24802963
[TBL] [Abstract][Full Text] [Related]
3. Decreased proportions of CD4 + IL17+/CD4 + CD25 + CD127- and CD4 + IL17+/CD4 + CD25 + CD127 - FoxP3+ T cells in children with autoimmune thyroid diseases (.).
Bossowski A; Moniuszko M; Idźkowska E; Grubczak K; Singh P; Bossowska A; Diana T; Kahaly GJ
Autoimmunity; 2016 Aug; 49(5):320-8. PubMed ID: 27206624
[TBL] [Abstract][Full Text] [Related]
4. Analysis of circulating T gamma/delta lymphocytes and CD16/56 cell populations in children and adolescents with Graves' disease.
Bossowski A; Urban M; Stasiak-Barmuta A
Pediatr Res; 2003 Sep; 54(3):425-9. PubMed ID: 12761360
[TBL] [Abstract][Full Text] [Related]
5. Impact of treatment with methimazole on the Bcl-2 expression in CD8+ peripheral blood lymphocytes in children with Graves' disease.
Klatka M; Grywalska E; Polak A; Roliński J
Ann Agric Environ Med; 2013; 20(4):884-8. PubMed ID: 24364474
[TBL] [Abstract][Full Text] [Related]
6. Impact of methimazole treatment on magnesium concentration and lymphocytes activation in adolescents with Graves' disease.
Klatka M; Grywalska E; Partyka M; Charytanowicz M; Rolinski J
Biol Trace Elem Res; 2013 Jun; 153(1-3):155-70. PubMed ID: 23661330
[TBL] [Abstract][Full Text] [Related]
7. Relationship between CTLA-4 and CD28 molecule expression on T lymphocytes and stimulating and blocking autoantibodies to the TSH-receptor in children with Graves' disease.
Bossowski A; Stasiak-Barmuta A; Urban M
Horm Res; 2005; 64(4):189-97. PubMed ID: 16220002
[TBL] [Abstract][Full Text] [Related]
8. Absolute reduction in peripheral regulatory T cells in patients with Graves' disease and post-treatment recovery.
Liu HY; Shi ZY; Fan D; Zhang SX; Wu LX; Lu KY; Yang SY; Li WT; Kang JF; Li CH; Cheng ZH; Xue Y; Wu ZF; Li XF; Li SJ
Mol Immunol; 2022 Apr; 144():49-57. PubMed ID: 35189399
[TBL] [Abstract][Full Text] [Related]
9. Impaired immune regulation after radioiodine therapy for Graves' disease and the protective effect of Methimazole.
Côté-Bigras S; Tran V; Turcotte S; Rola-Pleszczynski M; Verreault J; Rottembourg D
Endocrine; 2016 Jun; 52(3):587-96. PubMed ID: 26701678
[TBL] [Abstract][Full Text] [Related]
10. Methimazole treatment in Graves' disease: behaviour of CD5+B lymphocytes and regulatory T cell subsets.
Paggi A; Amoroso A; Ferri GM; Mariotti A; Pellegrino C; Afeltra A
Eur Rev Med Pharmacol Sci; 1998; 2(1):11-9. PubMed ID: 9825565
[TBL] [Abstract][Full Text] [Related]
11. Regulatory T cells but not T helper 17 cells are modulated in an animal model of Graves' hyperthyroidism.
Zhou J; Bi M; Fan C; Song X; Yang R; Zhao S; Li L; Li Y; Teng W; Shan Z
Clin Exp Med; 2012 Mar; 12(1):39-46. PubMed ID: 21544672
[TBL] [Abstract][Full Text] [Related]
12. Expression of very late antigen-4 and lymphocyte function-associated antigen-1 on peripheral blood lymphocytes from patients with graves disease.
Bossowski A; Urban M; Stasiak-Barmuta A; Turowski D
Pediatr Res; 2002 Oct; 52(4):533-7. PubMed ID: 12357047
[TBL] [Abstract][Full Text] [Related]
13. Serial analysis of the effects of methimazole therapy on circulating B cell subsets in Graves' disease.
Corrales JJ; Orfao A; López A; Ciudad J; Mories MT
J Endocrinol; 1996 Nov; 151(2):231-40. PubMed ID: 8958783
[TBL] [Abstract][Full Text] [Related]
14. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
Antonelli A; Rotondi M; Fallahi P; Romagnani P; Ferrari SM; Barani L; Ferrannini E; Serio M
Clin Endocrinol (Oxf); 2006 Feb; 64(2):189-95. PubMed ID: 16430719
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulation by methimazole therapy in Graves' disease: rapid changes in activation stage of circulating regulatory T cell subsets, B cells and NK cells.
Karlsson FA; Tötterman TH
Clin Exp Immunol; 1988 Nov; 74(2):258-63. PubMed ID: 2906281
[TBL] [Abstract][Full Text] [Related]
16. Methimazole therapy in Graves' disease influences the abnormal expression of CD69 (early activation antigen) on T cells.
Corrales JJ; López A; Ciudad J; Mories MT; Miralles JM; Orfao A
J Endocrinol; 1997 Dec; 155(3):491-500. PubMed ID: 9487994
[TBL] [Abstract][Full Text] [Related]
17. Induction of circulating activated suppressor-like T cells by methimazole therapy for Graves' disease.
Tötterman TH; Karlsson FA; Bengtsson M; Mendel-Hartvig I
N Engl J Med; 1987 Jan; 316(1):15-22. PubMed ID: 2946953
[TBL] [Abstract][Full Text] [Related]
18. Immune regulatory cells and IL17-producing lymphocytes in patients with benign and malignant salivary gland tumors.
Haghshenas MR; Khademi B; Faghih Z; Ghaderi A; Erfani N
Immunol Lett; 2015 Apr; 164(2):109-16. PubMed ID: 25739075
[TBL] [Abstract][Full Text] [Related]
19. Decreased Treg Cell and TCR Expansion Are Involved in Long-Lasting Graves' Disease.
Chen Z; Liu Y; Hu S; Zhang M; Shi B; Wang Y
Front Endocrinol (Lausanne); 2021; 12():632492. PubMed ID: 33912135
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of CD4+CD161+CD196+ and CD4+IL-17+ Th17 cells in the peripheral blood of young patients with Hashimoto's thyroiditis and Graves' disease].
Bossowski A; Moniuszko M; Idźkowska E; Dąbrowska M; Jeznach M; Sawicka B; Borysewicz-Sańczyk H; Bossowska A; Rusak M; Bodzenta-Łukaszyk A
Pediatr Endocrinol Diabetes Metab; 2012; 18(3):89-95. PubMed ID: 23146786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
